Answers are grounded in this paper and cite their sources.
Objective: This study aimed to develop and evaluate sophorolipid-stabilized, thioketal-gated nanostructured lipid carriers (SL-NLCs) for oral delivery of celecoxib with reactive oxygen species (ROS)-responsive drug release, improved bioavailability, and joint-targeted therapeutic efficacy in collagen-induced arthritis (CIA) models. Methods: SL-NLCs were formulated using a microfluidic ethanol injection method incorporating a thioketal (TK-PEG-Chol) linker to achieve ROS sensitivity. Physicochemical characterization, mucus penetration, and Caco-2 transport studies were performed, along with in vitro anti-inflammatory evaluation, pharmacokinetic analysis, and in vivo therapeutic assessment in CIA rats. Results: The optimized SL-NLCs exhibited uniform spherical morphology, high encapsulation efficiency (>91%), and ROS-triggered accelerated drug release. Enhanced mucosal diffusivity (0.85 µm²/s) and approximately 5.2-fold higher epithelial permeability (Papp) were observed compared to the free drug. The SL-NLC(TK) formulation improved oral bioavailability of celecoxib by approximately 3.5-fold and demonstrated preferential accumulation in synovial tissue. Significant reductions in TNF-α, IL-6, and oxidative stress markers were observed, along with restoration of antioxidant enzyme levels. Joint protection and tissue recovery were confirmed through micro-CT and histological analysis. Conclusion: Sophorolipid-stabilized, thioketal-gated nanocarriers significantly enhance oral bioavailability, enable ROS-responsive drug release, and provide targeted anti-arthritic effects, demonstrating a sustainable and translational nanomedicine platform for rheumatoid arthritis therapy.
No takes yet. Share an insight, caveat, or question.
PRADEEPA et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: